RNF187

Summary

RNF187 (ring finger protein 187, HGNC:27146) is a protein-coding gene on chromosome 1q42.13, encoding E3 ubiquitin-protein ligase RNF187 (Q5TA31). E3 ubiquitin-protein ligase that acts as a coactivator of JUN-mediated gene activation in response to growth factor signaling via the MAP3K1 pathway, independently from MAPK8.

Enables ubiquitin-protein transferase activity. Involved in positive regulation of DNA-templated transcription; proteasome-mediated ubiquitin-dependent protein catabolic process; and protein ubiquitination. Located in cytosol and nucleoplasm.

Source: NCBI Gene 149603 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 37 total
• MANE Select transcript: NM_001010858

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:27146
Approved symbol	RNF187
Name	ring finger protein 187
Location	1q42.13
Locus type	gene with protein product
Status	Approved
Aliases	RACO1, RACO-1
Ensembl gene	ENSG00000168159
Ensembl biotype	protein_coding
OMIM	613754
Entrez	149603

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 1 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000305943, ENST00000482739

RefSeq mRNA: 1 — MANE Select: NM_001010858 NM_001010858

CCDS: CCDS76271

Canonical transcript exons

ENST00000305943 — 4 exons

Exon	Start	End
ENSE00001121113	228488960	228489052
ENSE00001121118	228487382	228487878
ENSE00003467003	228493883	228496188
ENSE00003605816	228493053	228493274

Expression profiles

Bgee: expression breadth ubiquitous, 141 present calls, max score 98.07.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 94.5132 / max 443.5962, expressed in 1827 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
8951	91.1092	1826
8952	1.0264	666
8956	0.8341	392
8954	0.7630	422
8953	0.4477	252
8955	0.3326	140

Top tissues by expression

141 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right frontal lobe	UBERON:0002810	98.07	gold quality
superior frontal gyrus	UBERON:0002661	98.00	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	97.91	gold quality
anterior cingulate cortex	UBERON:0009835	97.79	gold quality
Brodmann (1909) area 9	UBERON:0013540	97.79	gold quality
primary visual cortex	UBERON:0002436	97.74	gold quality
hypothalamus	UBERON:0001898	97.32	gold quality
nucleus accumbens	UBERON:0001882	97.29	gold quality
right hemisphere of cerebellum	UBERON:0014890	97.22	gold quality
cerebellum	UBERON:0002037	97.18	gold quality
temporal lobe	UBERON:0001871	97.17	gold quality
putamen	UBERON:0001874	97.17	gold quality
right adrenal gland cortex	UBERON:0035827	97.16	gold quality
amygdala	UBERON:0001876	97.15	gold quality
cerebellar cortex	UBERON:0002129	97.15	gold quality
cerebellar hemisphere	UBERON:0002245	97.14	gold quality
caudate nucleus	UBERON:0001873	97.09	gold quality
Ammon’s horn	UBERON:0001954	97.07	gold quality
cortical plate	UBERON:0005343	97.06	gold quality
right adrenal gland	UBERON:0001233	96.83	gold quality
substantia nigra	UBERON:0002038	96.51	gold quality
left adrenal gland	UBERON:0001234	96.49	gold quality
left adrenal gland cortex	UBERON:0035825	96.44	gold quality
lower esophagus mucosa	UBERON:0035834	96.05	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	95.90	gold quality
embryo	UBERON:0000922	95.38	gold quality
ganglionic eminence	UBERON:0004023	95.38	gold quality
apex of heart	UBERON:0002098	95.36	gold quality
hindlimb stylopod muscle	UBERON:0004252	95.25	gold quality
stromal cell of endometrium	CL:0002255	95.12	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.88
E-CURD-112	no	2.88

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

73 targeting RNF187, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3134	100.00	66.43	777
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-1229-3P	99.97	66.49	906
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-3605-5P	99.96	67.12	932
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-6744-5P	99.93	66.82	748
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-300	99.92	71.76	2856
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-6752-3P	99.72	66.71	1587
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-30B-3P	99.70	65.76	2325
HSA-MIR-3689A-3P	99.70	65.73	2306
HSA-MIR-3689B-3P	99.70	65.71	2311
HSA-MIR-3689C	99.70	65.71	2311
HSA-MIR-6779-5P	99.70	65.76	2363
HSA-MIR-3202	99.66	67.70	2737
HSA-MIR-3158-5P	99.65	67.51	1763
HSA-MIR-6512-3P	99.65	66.07	1468

Literature-anchored findings (GeneRIF, showing 8)

• The RACO-1(RING domain AP-1 co-activator-1) is a co-activator that links c-Jun to growth factor signalling and is essential for AP-1 function in proliferation (PMID:20852630)
• Arginine methylation of RACO-1 is required for efficient transcriptional activation by c-Jun/AP-1 and thus identify PRMT1 as an important regulator of c-Jun/AP-1 function. (PMID:23624934)
• elevated RNF187 expression promotes NSCLC development by inducing cell EMT and apoptosis resistance, and RNF187 may be a novel prognostic indicator for NSCLC patients after curative resection (PMID:30624778)
• we identified that RNF187 is an essential factor for Notch1 to promote invasion and metastasis of HCC. Of highly clinical relevance, we found that activation of Notch1-RNF187 correlates with a worse prognosis of HCC patients. (PMID:31477177)
• RING finger protein 187 as a novel potential biomarker for predicting the prognosis of ovarian carcinoma in 2 cancer centers. (PMID:32057463)
• RACO-1 modulates Hippo signalling in oesophageal squamous cell carcinoma. (PMID:32896069)
• Regulation of P53 signaling in breast cancer by the E3 ubiquitin ligase RNF187. (PMID:35165289)
• Immune infiltration is associated with pan-cancer prognostic biomarker RING finger protein 187. (PMID:38167828)

Cross-species orthologs

0 orthologs

Protein

Protein identifiers

E3 ubiquitin-protein ligase RNF187 — Q5TA31 (reviewed: Q5TA31)

Alternative names: RING domain AP1 coactivator 1, RING finger protein 187, RING-type E3 ubiquitin transferase RNF187

All UniProt accessions (2): A0A1X7SBW3, Q5TA31

UniProt curated annotations — full annotation on UniProt →

Function. E3 ubiquitin-protein ligase that acts as a coactivator of JUN-mediated gene activation in response to growth factor signaling via the MAP3K1 pathway, independently from MAPK8.

Subunit / interactions. Homodimer. Interacts with JUN, independently of JUN phosphorylation. Interacts (via C-terminus) with TRIM7.

Subcellular location. Cytoplasm. Nucleus.

Post-translational modifications. Ubiquitinated; undergoes ‘Lys-48’-linked autoubiquitination in the absence of growth factors and MAP3K1-induced ‘Lys-63’-linked polyubiquitination. ‘Lys-48’-autoubiquitination leads to degradation by the proteasome, while MAP3K1-induced ‘Lys-63’-linked polyubiquitination results in the stabilization of the protein. ‘Lys-48’- and ‘Lys-63’-linked polyubiquitinations occur most probably on the same 3 C-terminal lysine residues (Lys-195, Lys-223 and Lys-224) and are thus mutually exclusive. Other sites of ubiquitination are not excluded. ‘Lys-63’-linked polyubiquitination by TRIM7 in response to growth factor signaling via the MEK/ERK pathway enhances protein stability. Arginine methylation by PRMT1 stabilizes RNF187 by facilitating K63-linked ubiquitin chain formation, and enables dimerization, c-Jun interaction and subsequent AP1 target gene expression.

Domain organisation. The RING-type zinc finger domain is required for E3 ligase activity.

Pathway. Protein modification; protein ubiquitination.

RefSeq proteins (1): NP_001010858* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001841	Znf_RING	Domain
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR017907	Znf_RING_CS	Conserved_site
IPR050143	TRIM/RBCC	Family

Pfam: PF15227

UniProt features (16 total): mutagenesis site 8, cross-link 3, modified residue 2, chain 1, zinc finger region 1, helix 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
7OW2	X-RAY DIFFRACTION	2.17

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5TA31-F1	71.63	0.28

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 98, 109, 195, 223, 224

Mutagenesis-validated functional residues (8):

Position	Phenotype
98	abolishes ubiquitination by trim7; when associated with k-109.
109	abolishes ubiquitination by trim7; when associated with k-98.
195	no detectable effect on ubiquitination. marked decrease in ubiquitination, but no effect on subcellular location; when a
223	no detectable effect on ubiquitination. marked decrease in ubiquitination, but no effect on subcellular location; when a
224	no detectable effect on ubiquitination. marked decrease in ubiquitination, but no effect on subcellular location; when a
1	loss of protein expression.
12	increased rnf187 stability and reduced polyubiquitination; when associated with a-15.
15	increased rnf187 stability and reduced polyubiquitination; when associated with a-12.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 141 (showing top): GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_DN, PATIL_LIVER_CANCER, SENESE_HDAC1_AND_HDAC2_TARGETS_DN, CADWELL_ATG16L1_TARGETS_DN, GOBP_PROTEIN_AUTOUBIQUITINATION, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, GOBP_PROTEIN_POLYUBIQUITINATION, NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN, GOBP_PROTEASOMAL_PROTEIN_CATABOLIC_PROCESS, GOBP_PROTEIN_K48_LINKED_UBIQUITINATION, GOBP_PROTEIN_CATABOLIC_PROCESS, GOBP_PROTEOLYSIS, GOMF_ACYLTRANSFERASE_ACTIVITY, GOMF_AMINOACYLTRANSFERASE_ACTIVITY

GO Biological Process (6): positive regulation of cell population proliferation (GO:0008284), proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161), positive regulation of DNA-templated transcription (GO:0045893), protein autoubiquitination (GO:0051865), protein K48-linked ubiquitination (GO:0070936), protein ubiquitination (GO:0016567)

GO Molecular Function (6): ubiquitin-protein transferase activity (GO:0004842), zinc ion binding (GO:0008270), ubiquitin protein ligase activity (GO:0061630), protein binding (GO:0005515), transferase activity (GO:0016740), metal ion binding (GO:0046872)

GO Cellular Component (4): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), cytosol (GO:0005829)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
cell population proliferation	1
regulation of cell population proliferation	1
positive regulation of cellular process	1
ubiquitin-dependent protein catabolic process	1
proteasomal protein catabolic process	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
positive regulation of RNA biosynthetic process	1
protein ubiquitination	1
protein polyubiquitination	1
protein modification by small protein conjugation	1
ubiquitin-like protein transferase activity	1
transition metal ion binding	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
binding	1
catalytic activity	1
cation binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

500 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RNF187	MAP2K2	P36507	544
RNF187	MAP3K1	Q13233	510
RNF187	ANGEL1	Q9UNK9	491
RNF187	JUN	P05412	475
RNF187	MAP2K1	Q02750	424
RNF187	EIF4H	Q15056	402
RNF187	HRAS	P01112	383
RNF187	DCAF4	Q8WV16	353
RNF187	ELF3	P78545	338
RNF187	EEIG1	Q5T9C2	332
RNF187	RAMP3	O60896	328
RNF187	ZNF213	O14771	325
RNF187	USP47	Q96K76	323
RNF187	SHARPIN	Q9H0F6	322
RNF187	RNF157	Q96PX1	317

IntAct

48 interactions, top by confidence:

A	B	Type	Score
	TOMM70	psi-mi:“MI:0914”(association)	0.980
CUL2	VHL	psi-mi:“MI:0914”(association)	0.940
CUL5	SOCS7	psi-mi:“MI:0914”(association)	0.640
TRIM44	CUL2	psi-mi:“MI:0914”(association)	0.640
RNF187	ZNF835	psi-mi:“MI:0915”(physical association)	0.560
RNF187	ZNF417	psi-mi:“MI:0915”(physical association)	0.560
TRIM44	ODAD3	psi-mi:“MI:0914”(association)	0.530
ZNF562	ISLR	psi-mi:“MI:0914”(association)	0.530
ZBTB42	MID1	psi-mi:“MI:0914”(association)	0.530
ZNF669	LRP4	psi-mi:“MI:0914”(association)	0.530
WDR83	SH2B2	psi-mi:“MI:0914”(association)	0.530
CUL2	RNF187	psi-mi:“MI:0914”(association)	0.530
EDA	AP3B1	psi-mi:“MI:0914”(association)	0.530
LANCL3	RNF187	psi-mi:“MI:0915”(physical association)	0.400
RNF187	RNF187	psi-mi:“MI:0915”(physical association)	0.400
CUL2	ANXA2P2	psi-mi:“MI:0914”(association)	0.350
NEDD8	DDX3X	psi-mi:“MI:0914”(association)	0.350
LHX6	KDM5C	psi-mi:“MI:0914”(association)	0.350
WDR83	PIKFYVE	psi-mi:“MI:0914”(association)	0.350
S100A2	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
S100P	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
ZNF460	ZNF320	psi-mi:“MI:0914”(association)	0.350

BioGRID (107): RNF187 (Affinity Capture-RNA), RNF187 (Affinity Capture-RNA), RNF187 (Affinity Capture-MS), RNF187 (Affinity Capture-MS), RNF187 (Affinity Capture-MS), RNF187 (Affinity Capture-MS), RNF187 (Affinity Capture-MS), RNF187 (Affinity Capture-MS), RNF187 (Affinity Capture-MS), RNF187 (Affinity Capture-MS), RNF187 (Affinity Capture-MS), RNF187 (Affinity Capture-MS), RNF187 (Affinity Capture-MS), RNF187 (Affinity Capture-MS), RNF187 (Two-hybrid)

ESM2 similar proteins: A0JPQ4, B1WC39, D3Z8N2, E1BD59, G3MY25, O15553, O77666, P59044, P62603, Q12899, Q14142, Q1XH17, Q1XH18, Q1XHT8, Q3UWA4, Q499M4, Q53EQ6, Q5NCC3, Q5RBG2, Q5RKG6, Q5TA31, Q5TM52, Q5TM55, Q6MFY8, Q6P9F5, Q6ZMU5, Q7YR31, Q7YR33, Q7YR34, Q86XR2, Q8BFX1, Q8BVW3, Q8C006, Q8C0E3, Q8NG06, Q8WV44, Q8WZA9, Q920M2, Q923T7, Q96IU2

Diamond homologs: A0JPQ4, A6QQX5, D3YY23, D3Z8N2, F6ZQ54, F8S122, O00478, O00481, O60858, O75677, P18892, P82885, P83234, Q13410, Q14258, Q17RB8, Q1XH17, Q1XH18, Q27J48, Q2XXL4, Q32L60, Q503I2, Q5EBN2, Q5M7V1, Q5R846, Q5R996, Q5TA31, Q5ZMD4, Q61510, Q62556, Q640S6, Q6PGR9, Q6QA27, Q6UX41, Q6UXG8, Q6ZMU5, Q7SZN2, Q7T308, Q7TST0, Q810I1

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
Ub:E2	“up-regulates activity”	RNF187	ubiquitination
TRIM7	“up-regulates quantity by stabilization”	RNF187	ubiquitination

Disease & clinical

Clinical variants and AI predictions

ClinVar

37 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	28
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

734 predictions. Top by Δscore:

Variant	Effect	Δscore
1:228488958:A:AG	acceptor_gain	1.0000
1:228488958:A:T	acceptor_loss	1.0000
1:228488959:G:GG	acceptor_gain	1.0000
1:228493049:GCAG:G	acceptor_loss	1.0000
1:228493051:A:AG	acceptor_gain	1.0000
1:228493051:AG:A	acceptor_gain	1.0000
1:228493052:G:GG	acceptor_gain	1.0000
1:228493052:GG:G	acceptor_gain	1.0000
1:228493270:TGCAG:T	donor_loss	1.0000
1:228493272:CAG:C	donor_loss	1.0000
1:228493273:AGG:A	donor_loss	1.0000
1:228493274:GGTGC:G	donor_loss	1.0000
1:228493276:T:A	donor_loss	1.0000
1:228487860:G:GT	donor_gain	0.9900
1:228488958:AG:A	acceptor_gain	0.9900
1:228488959:GG:G	acceptor_gain	0.9900
1:228488959:GGA:G	acceptor_gain	0.9900
1:228488959:GGAGA:G	acceptor_gain	0.9900
1:228489027:C:T	donor_gain	0.9900
1:228489049:G:GT	donor_gain	0.9900
1:228489049:GAAGG:G	donor_loss	0.9900
1:228489050:AAGGC:A	donor_loss	0.9900
1:228489051:AGGCA:A	donor_loss	0.9900
1:228489052:GGCA:G	donor_loss	0.9900
1:228489054:CAAG:C	donor_loss	0.9900
1:228493041:A:AG	acceptor_gain	0.9900
1:228493041:ACCC:A	acceptor_gain	0.9900
1:228493044:C:A	acceptor_gain	0.9900
1:228493048:T:A	acceptor_gain	0.9900
1:228493051:AGG:A	acceptor_gain	0.9900

AlphaMissense

1518 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:228489005:G:C	A146P	0.996
1:228493102:T:C	L178P	0.996
1:228487633:T:C	C49R	0.994
1:228487568:G:A	C27Y	0.992
1:228487579:T:C	F31L	0.992
1:228487581:C:A	F31L	0.992
1:228487581:C:G	F31L	0.992
1:228487592:G:A	C35Y	0.992
1:228489015:T:C	L149P	0.992
1:228489026:G:C	A153P	0.992
1:228487634:G:A	C49Y	0.990
1:228487635:C:G	C49W	0.990
1:228493114:T:C	F182S	0.990
1:228493069:G:C	R167P	0.989
1:228493092:T:G	Y175D	0.989
1:228487583:G:A	C32Y	0.988
1:228487593:C:G	C35W	0.988
1:228487569:C:G	C27W	0.987
1:228487580:T:C	F31S	0.987
1:228487582:T:C	C32R	0.987
1:228489006:C:A	A146D	0.987
1:228493073:G:C	R168S	0.987
1:228493073:G:T	R168S	0.987
1:228493231:T:C	L221P	0.987
1:228489009:G:C	R147P	0.986
1:228489047:T:A	W160R	0.986
1:228489047:T:C	W160R	0.986
1:228489049:G:C	W160C	0.986
1:228489049:G:T	W160C	0.986
1:228487591:T:C	C35R	0.985

dbSNP variants (sampled 300 via entrez): RS1002105591 (1:228486868 C>A,T), RS1003075801 (1:228485977 G>A), RS1004283621 (1:228485760 T>C,G), RS1004717393 (1:228485424 T>C), RS1005727431 (1:228486632 C>A), RS1006110424 (1:228486411 G>C), RS1006476921 (1:228487495 C>G,T), RS1008199328 (1:228487572 C>G,T), RS1008315297 (1:228493121 G>A,T), RS1008663824 (1:228486630 G>A,T), RS1009047422 (1:228486819 G>T), RS1009911191 (1:228487337 C>A,T), RS1010501417 (1:228486284 G>T), RS1012237162 (1:228486043 G>T), RS1012374398 (1:228485795 T>C)

Disease associations

OMIM: gene MIM:613754 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST002198_8	Tuberculosis	2.000000e-07
GCST009246_130	Cerebrospinal fluid sTREM-2 levels	4.000000e-12

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0010151	soluble triggering receptor expressed on myeloid cells 2 measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, increases methylation	4
Cyclosporine	increases expression	2
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	increases expression	1
perfluorooctanoic acid	decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, increases expression	1
N,N,N’,N’-tetrakis(2-pyridylmethyl)ethylenediamine	decreases expression	1
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	decreases stability	1
Ro 31-8220	decreases reaction, decreases stability	1
di-n-butylphosphoric acid	affects expression	1
benzyloxycarbonylleucyl-leucyl-leucine aldehyde	decreases reaction, decreases stability	1
perfluorooctane sulfonic acid	increases expression	1
perfluoro-n-nonanoic acid	increases expression	1
U 0126	decreases stability	1
Sunitinib	increases expression	1
Acetaminophen	increases expression	1
Arsenic	affects methylation	1
Cadmium	increases expression	1
Coumestrol	affects cotreatment, increases expression	1
Dexamethasone	decreases expression	1
Hydralazine	affects cotreatment, increases expression	1
Lead	affects expression	1
Silicon Dioxide	decreases methylation	1
Smoke	decreases expression	1
Tetradecanoylphorbol Acetate	decreases reaction, increases expression	1
Thiram	decreases expression	1
Tretinoin	decreases expression	1
Antirheumatic Agents	increases expression	1
Cadmium Chloride	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.